Table 1.

Rates of MRD-negative responses and 2-year PFS rates, assessed at landmarks of postinduction, post-ASCT, and postconsolidation time points, in patients achieving CR, uCR, and VGPR

Best response at time pointP value for comparison
CR*uCRVGPRCR vs uCRuCR vs VGPRCR vs VGPR
MRD assessment
 Postinduction, N evaluable1266997
 MRD-negative rate, n (%)66 (52%)40 (58%)15 (15%).4<.0001<.0001
 Post-ASCT, N evaluable12397105
 MRD-negative rate, n (%)84 (68%)76 (78%)30 (29%).1<.0001<.0001
 Postconsolidation, N evaluable10311380
 MRD-negative rate, n (%)78 (76%)85 (75%)22 (28%).9<.0001<.0001
PFS
 From postinduction time point; median follow-up 31.1 mo, N12972106
 2-y PFS rate (95% CI)93% (88-97)88% (81-94)78% (69-86).5.001.02
 From ASCT time point, median follow-up 26.4 mo, N133105116
 2-y PFS rate (95% CI)88% (82-94)87% (81-94)77% (68-85).7.05.1
 From postconsolidation time point, median follow-up 23.5 mo, N14911885
 2-y PFS rate (95% CI)85% (80-96)88% (82-95)76% (68-85).4.1.3
  • CI, confidence interval.

  • * CR includes patients in stringent CR in the following proportions: post-induction, 64%; post-ASCT, 76%; and postconsolidation, 79%.